期刊文献+

非小细胞肺癌患者血浆纤维蛋白原检测的临床意义 被引量:2

Clinical significance of plasma fibrinogen level detection in non-small cell lung cancer patients
暂未订购
导出
摘要 目的探讨非小细胞肺癌(NSCLC)患者血浆纤维蛋白原水平与肺癌临床病理特征关系及预后的相关性。方法对55例NSCLC患者及20例健康人的血浆纤维蛋白原分别进行测定。结果NSCLC患者血浆纤维蛋白原水平显著高于健康对照组(P<0.01),肺癌患者血浆纤维蛋白原水平与患者的病理类型、TNM分期之间无明显关系。NSCLC患者血浆纤维蛋白原水平与其生存期之间有显著的负相关(r=-0.37,P<0.01)。结论NSCLC患者存在血浆纤维蛋白原水平增高,血液存在高凝状态;血浆纤维蛋白原水平与患者的生存期呈负相关,血浆纤维蛋白原是反映NSCLC患者预后的重要指标。 Objective To study the relationship between plasma fibrinogen level on pathophysiological characteristics and prognosis in patients with non-small cell lung cancer. Methods The plasma levels of fibrinogen were detected in fifty-five patients with non-small cell lung cancer and twenty normal controls. Results The plasma levels of fibrinogen in patients with non-small cell lung cancer were significantly higher than those of normal controls( P 〈 0. 001 ). The plasma levels of fibrinogen in patients with non-small cell lung cancer were not related to histological classification or P-TNM stages. The plasma levels of fibrinogen in patients with non-small cell lung cancer were negatively correlated to the survival span( r = -0.37, P〈0.01). Conclusions Elevation of plasma levels of fibrinogen exists in patients with non-small cell lung cancer. The elevated plasma fib- rinogen level may be associated with hypercoagulability state; the plasma levels of fibrinogen were negatively correlated to the survival span in patients with non-small cell lung cancer and they were important marker of prognosis of patients with non-small cell lung cancer.
出处 《实用临床医药杂志》 CAS 2009年第4期15-17,共3页 Journal of Clinical Medicine in Practice
关键词 非小细胞肺癌(NSCLC) 纤维蛋白原 预后 non-small cell lung cancer plasma fibrinogen prognosis
  • 相关文献

参考文献17

二级参考文献46

共引文献51

同被引文献21

  • 1陈军,方芸,张海霞,黄莉莉,钱晓萍,刘宝瑞.雾化吸入羟基喜树碱在兔体内的组织分布[J].药学学报,2004,39(9):747-751. 被引量:12
  • 2王红梅,廖国清,雷红,刘鹏辉,曲怡梅,刘士欣,解国清,李亮亮.晚期肺癌患者肺部感染病原学分析[J].第三军医大学学报,2006,28(20):2103-2104. 被引量:14
  • 3沈荣林,李旭.肺癌的不同病理类型与COPD的关系探讨[J].重庆医学,2006,35(23):2151-2152. 被引量:6
  • 4邹小农.中国肺癌流行病学[J].中华肿瘤防治杂志,2007,14(12):881-883. 被引量:152
  • 5Jonathan B,Anand P,Chen S. Psoas muscle metastases in non-small cell lung cancer[J].J Thorac Dis,2012,(01):83-87.
  • 6Michael EW,Wani MC,Cook CE. Antitumor agent Ⅰ:the isolation and structure of Camptothecin,anovel alkaloidal leukemia and tumor inhibitor fromcamptotheca acuminata[J].Journal of the American Chemical Society,1966,(16):3888.
  • 7Montoro P,Maldini M,Piacents S. Metabolite fingerprinting of Camptotheca acuminata and the HPLC-ESI-MS/MS analysis of camptothecin and related alkaloids[J].Journal of Pharmaceutical and Biomedical Analysis,2010,(51):405-415.
  • 8Koshkina NV,Gilbert BE,Waldrep JC. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice[J].Cancer Chemother Phar macol,1999,(03):187-192.
  • 9Gagnadoux F,Hureaux J,Vecellio L. Aerosolized chemotherapy[J].J Aerosol Med Pulm Drug Deliv,2008,(01):61-70.
  • 10Hu W,Zhang C,Fang Y. Anticancer properties of 10-hydroxycamptothecin in a murine melanoma pulmonary metastasis model in vitro and in vivo[J].Toxicology in Vitro,2011,(02):513-520.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部